Valneva SE
🇫🇷 VLA.PA · Paris · FR0004056851
Healthcare
EUR 2.71 price at analysis
Scores
Key Metrics
Powered by EODHDP/E (TTM)
N/A
P/E (Price-to-Earnings)Shows how much investors pay for each $1 of profit. We display the TTM P/E (Trailing Twelve Months) which uses actual earnings from the last 4 quarters. This is more reliable than Forward P/E which uses analyst estimates.
TTM period through: 2025-12-31
Why N/A?
EPS (TTM) = -0.68 (negative or zero)
Cannot calculate P/E with negative earnings.
Forward P/E (estimated): 666.7
Based on analyst estimates
Reference: Provider P/E (Forward): 666.7
ROE
-80.2%
ROE (Return on Equity)A profitability measure: how much profit is generated from shareholders’ equity. Higher isn’t always better if it comes from high debt.
EV/EBITDA
26.9x
EV/EBITDAA valuation ratio that compares total business value (including debt) to EBITDA. Lower can mean cheaper, but context matters.
Summary
Valneva SE is a specialized vaccine developer operating a cash-burning biotech model that fundamentally contradicts conservative dividend investing principles. With persistent negative free cash flow (-€42.3M) and structural unprofitability over the past decade, the stock offers no income or stability. Not recommended for new positions, as the extreme valuation multiples and lack of dividends make it entirely unsuitable for an income-focused portfolio.
Sector Context
Valneva SE is a commercial-stage vaccine company that researches, develops, and commercializes prophylactic vaccines for infectious diseases. While the broader healthcare sector can offer defensive characteristics, clinical-stage and specialized biotech firms operate high cash-burn models entirely unsuitable for conservative dividend strategies seeking predictable, recurring cash flows.
📊 Strategy Analysis
- • The company operates in a structurally important healthcare niche, developing specialized vaccines for infectious diseases with significant unmet medical needs.
- • Successfully generated substantial capital influxes periodically through the sale of Priority Review Vouchers to fund ongoing operations.
⚠ What to Watch
- • Fundamentally incompatible with a dividend income strategy due to severe cash burn, featuring trailing Free Cash Flow of -€42.3 million and zero dividend distributions.
- • Structural unprofitability is evident with net losses reported in 9 of the past 10 years, reflecting a highly speculative biotech business model.
- • Valuation metrics provide no margin of safety, highlighted by negative TTM earnings (-0.68 EPS), an extreme Forward P/E of 666.67x, and a deeply negative ROE of -80.16%.
📊 Historical Trends (10 Years)
Powered by EODHDThese charts show how key metrics have evolved over the past decade, helping you identify if the company is improving or deteriorating.
Debt Evolution (Net Debt / EBITDA)
Lower values are better. A declining trend indicates the company is reducing its debt (deleveraging).
Revenue & Earnings Growth
Consistent growth in revenueRevenue
The money a company brings in from selling its products or services. It’s the top line before costs. (blue) and earningsEarnings (Profit)
What’s left after expenses. Positive earnings mean the business made a profit; negative means a loss. (green) indicates a healthy business. Look for upward trends and recoveries after temporary dips.
Dividend Sustainability (FCF vs Dividends Paid)
Free cash flowFree Cash Flow
Cash left after the company pays for running the business and maintaining it. Often used to fund dividends, pay debt, or buy back shares. (FCFFCF (Free Cash Flow)
Short for Free Cash Flow: cash left after operating needs and maintenance spending., blue) should cover dividends paidDividends Paid
Cash the company paid out to shareholders. It’s not guaranteed and can change over time. (green). If dividends consistently exceed FCFFCF (Free Cash Flow)
Short for Free Cash Flow: cash left after operating needs and maintenance spending., the dividend may be at risk.
Analysis date: 2026-04-05
Disclaimer: This information is for educational purposes only. Not financial advice.